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Aims Our study aimed to examine the management of acute coronary syndromes (ACS) in Europe and the
Mediterranean basin, and to compare adherence to guidelines with that reported in the ﬁrst Euro Heart
Survey on ACS (EHS–ACS-I), 4 years earlier.
Methods and results In a prospective survey conducted in 2004 (EHS–ACS-II), data describing the
characteristics, treatment, and outcome of 6385 patients diagnosed with ACS in 190 medical centres
in 32 countries were collected. ACS with ST-elevation was the initial diagnosis in 47% of patients, no
ST-elevation in 48%, and undetermined electrocardiographic pattern in 5% of patients. Comparison of
data collected in 2000 and 2004 showed similar baseline characteristics, but greater use of recom-
mended medications and coronary interventions in EHS–ACS-II. Among patients with ST-elevation, the
use of primary reperfusion increased slightly (from 56 to 64%), with a signiﬁcant shift from ﬁbrinolytic
therapy to primary percutaneous coronary intervention (PPCI). The use of PPCI rose from 37 to 59%
among those undergoing primary reperfusion therapy. Analysis of data in 34 centres that participated
in both surveys showed even greater improvement with respect to the use of recommended medical
therapy, interventions, and outcome.
Conclusion Data from EHS–ACS-II suggest an increase in adherence to guidelines for treatment of ACS in
comparison with EHS–ACS-I.
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Introduction
The diagnosis, management, and treatment of the various
forms of acute coronary syndromes (ACS), which include
persistent ST-segment elevation myocardial infarction (MI),
non-ST-segment elevation MI, and unstable angina (UA),
have been rapidly evolving in recent years. European and
American cardiological associations have published new
guidelines to address these changes in medical practice.1–4
Surveys and registries are an effective means of assessing
the implementation of guidelines.5 Although the adherence
to guidelines has been shown to be associated with improved
outcomes,6 their implementation remains sub- optimal.7,8
Indeed, the ﬁrst Euro Heart Survey of ACS,9 conducted in
25 countries in Europe and the Mediterranean basin in
2000–2001, demonstrated great variability in the implemen-
tation of the guidelines and recommendations applicable at
that time period. In order to assess current management and
implementation of more contemporary guidelines, we con-
ducted the second Euro Heart Survey of ACS during 2004 in
32 countries throughout this region.
& The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
*Corresponding author. Tel: þ972 3 5344703; fax: þ972 3 5342392.
E-mail address: behar@sheba.health.gov.il
European Heart Journal (2006) 27, 2285–2293
doi:10.1093/eurheartj/ehl196
Methods
The second Euro Heart Survey on ACS was conducted in 190 medical
centres from 32 countries in Europe and the Mediterranean basin.
Within each participating country, medical centres were invited to
participate in the survey on a purely voluntary basis, by a national
coordinator, responsible for maintaining contact with the investi-
gators in each of the participating centres, and for overseeing the
implementation of the survey protocol (see Appendix). In addition
to the recruitment efforts of the national coordinators, information
about the survey was posted on the website of the European Society
of Cardiology (ESC) and on the ESC web news, inviting all interested
investigators to join. Announcements about the survey were also
made at the European Congress of Cardiology. Among 319 centres
that conﬁrmed their participation in the survey, 129 either did not
recruit any patients or did not complete any case report forms.
The enrolment period of the survey began in March 2004, and
ended in October 2004. Participating centres were asked to
recruit 30–50 consecutive patients fulﬁlling the survey inclusion cri-
terion of a conﬁrmed diagnosis of ACS.
In each participating centre, a data collection ofﬁcer was respon-
sible for screening consecutive patients admitted with a tentative
diagnosis of ACS. Patients were followed throughout their hospi-
talization, and informed consent for participation in the survey
was acquired when necessary. As in the ﬁrst survey,9 case report
forms were completed only after the diagnosis of ACS (UA,
Q-wave, non-Q-wave, or undetermined MI) was conﬁrmed by the
attending physician. Patients with symptoms that suggested ACS,
but did not fulﬁl the diagnostic criteria for ACS were not included
in the survey.
In addition to data regarding the pre-hospital and in-hospital
course, follow-up data were collected at 30 days. Patient identiﬁ-
cation was not recorded on the case report forms. The centres
were instructed to keep a log of all included patients, in which
their names, contact information, and study code were recorded,
in order to enable follow-up. Each participating centre was also
asked to complete a questionnaire, designed to provide a descrip-
tion of the medical centre.9
Electronic case report forms were used for data entry and trans-
ferred via the web to a central database located in the European
Heart House, where they were edited for missing data, inconsisten-
cies, and outliers. Additional editing of the data was performed at
the data analysis centre at the Neufeld Cardiac Research
Institute. In the case of two countries, participation in ACS-II
involved the transfer of data collected in national ACS surveys
during the recruitment period of ACS-II in 2004 (the Israeli ACSIS
survey and the Spanish MASCARA survey10) to the ACS-II database
at the European Heart House. ACSIS is a biennial national ACS
survey conducted in all 25 operating cardiac departments in Israel
since 1992. MASCARA is a nationwide prospective cohort study
that included consecutive patients hospitalized for ACS in 60
randomly selected Spanish hospitals in 2004–2005. Both national
surveys collected data on ACS patients using similar case report
forms and the same deﬁnitions for ACS as used in EHS–ACS-II.
Of the 190 centres, 91 that participated in the survey were
afﬁliated with academic institutions, 123 had catheterization lab-
oratories, and 61 had cardiac surgery facilities. Fifty-three
percent of the patients were hospitalized in medical centres that
were afﬁliated with academic institutions, and 46% were hospita-
lized in tertiary care centres. Seventy-three percent of the patients
were treated in hospitals that had on-site catheterization labora-
tories, and 37% in centres that had facilities for cardiovascular
surgery. Seventy percent of the patients were hospitalized in
centres in which the policy was to hospitalize ACS patients in cardi-
ology departments, 26% were admitted to centres that treat ACS
patients in both cardiology and internal medicine departments,
and 4% were treated in centres that hospitalized ACS patients in
internal medicine wards. Examination of the extent of enrolment
in the participating centres showed that 71 centres (37%) recruited
less than 30 patients, 102 centres (54%) recruited 30–50 patients,
and 17 centres (9%) included more than 50 patients.
Among the centres participating in EHS–ACS-II were 34 centres
that had also participated in the ﬁrst European Heart Survey on
ACS. Analysis of the characteristics of 34 centres that participated
in both the EHS–ACS-I and EHS–ACS-II surveys, showed that the pro-
portion of patients hospitalized in centres with academic afﬁliations
(70%), catheterization laboratories (92%), and cardiac surgery facili-
ties (65%), were greater in comparison with the total group of
centres participating in EHS–ACS-II.
Statistical methods
All analyses were performed using SAS software (SAS Institute Inc.,
Cary, NC, USA). The x2 test was used for comparison of proportions.
All tests were two-sided and considered statistically signiﬁcant if
P  0.05. No adjustment was made for multiple testing.
Comparison of the outcome of patients included in the ACS-I and
ACS-II surveys was performed using logistic regression analysis
with adjustment for the following variables, which were considered
to be potential predictors of mortality on the basis of clinical judg-
ment, univariable analysis, and data from the literature: age, sex,
prior MI, diabetes, prior stroke, chronic renal failure, hypertension,
current and past smoking, Killip class 2 on admission, and ST
pattern on admission ECG (ST-elevation, no ST-elevation, or unde-
termined pattern on ECG). In a multivariable analysis for 34
centres that participated in both the EHS–ACS-I and EHS–ACS-II
surveys, a similar model was used, with the addition of the variable
‘center’.
Results
The EHS–ACS-II cohort included 6385 patients with a ﬁnal
diagnosis of ACS. Baseline, demographic, and clinical
characteristics of the EHS–ACS-I and EHS–ACS-II patients
are presented in Table 1. The proportion of patients with
an initial diagnosis of ACS with ST-elevation rose from 42%
in EHS–ACS-I to 47% in EHS–ACS-II, whereas no ST-elevation
ACS patients comprised 51% of the ACS-I participants and
48% of those included in ACS-II. Five percent and 6.5% of
the patients in ACS-II and ACS-I, respectively, presented
with an undetermined electrocardiographic (ECG) pattern,
which included left bundle branch block/right bundle
branch block (LBBB/RBBB), pacing, or severe left ventricular
(LV) hypertrophy (LVH) without typical ST changes.
Examination of the characteristics of all patients included
in the ﬁrst and second EHS surveys of ACS showed a consider-
able degree of similarity with respect to mean age (65.2 vs.
64.7 in ACS-I vs. ACS-II), proportion of men (67.5% in ACS-I
vs. 70.1% in ACS-II), and the proportion of patients with
risk factors. Comparison of the characteristics of the
patients in the 34 centres participating in both surveys
showed much similarity in the two periods. The only note-
worthy difference was the proportion of patients with
ST-elevation, which rose from 40% in ACS-I to 51% in ACS-II.
The most common presenting symptom among EHS–ACS-II
patients was typical angina, which was most prevalent in
patients with ST-elevation. Patients with an undetermined
ECG pattern were more likely to present with heart
failure. Comparison of data from the two surveys showed
that the proportion of patients presenting with typical
angina was higher in ACS-I than ACS-II, 86.8% and 80.8%,
respectively. In the second survey, more patients were hos-
pitalized in coronary care units (70 vs. 62.4%), whereas
fewer were treated in cardiology wards (19.1 vs. 22%), and
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in internal medicine wards (7 vs. 13.8%). The proportion of
patients hospitalized in other wards was 3.9% in ACS-II vs.
1.8% in ACS-I.
The frequency of chronic use of cardiovascular therapies
among patients prior to admission was lower among
ST-elevation patients in comparison with no ST-elevation
patients in both surveys. The proportions of patients receiv-
ing pre-hospital medication were similar in the two survey
periods, although slight increases in the use of
ACE-inhibitors/angiotensin-II receptor blockers and statins
were observed in EHS–ACS-II.
Coronary angiography, percutaneous coronary interven-
tions (PCIs), and intracoronary stents were used more fre-
quently in ACS-II than in ACS-I (Table 2). The increase in
the proportion of patients undergoing coronary angiography,
PCIs, and stent implantation among those hospitalized in the
34 centres was greater than in the full ACS-I and ACS-II
cohorts (from 60.5 to 82.3%, from 45.9 to 69.9%, and from
34.1 to 63.6% for patients with ST-elevation, respectively,
and from 54.3 to 72.1%, from 27.3 to 46.7%, and from 19.6
to 43.6% for no ST-elevation patients, respectively).
A greater proportion of patients received evidence-based
medications during their hospitalization and at discharge in
ACS-II compared with ACS-I, irrespective of their initial ECG
diagnosis (Table 3, Figures 1 and 2). The reasons recorded
for not prescribing evidence-based medications during
ACS-II showed that half of the small number of patients
who did not receive aspirin or beta-adrenergic blockers had
contraindications to the medications. In contrast, the most
frequent reason for not prescribing anticoagulants, ticlopi-
dine/clopidogrel, ACE-inhibitors, and statins, was the lack
of indication for treatment according to current guidelines.
Patients hospitalized in the 34 centres that participated in
both surveys were more likely to receive evidence-based medi-
cation in comparison with the whole survey population in
ACS-II, during hospitalization and upon discharge from hospi-
talization. Particularly noteworthy was an increase in the use
of ticlopidine/clopidogrel both in-hospital and at discharge.
Analysis of the time at which medication was initiated
among ST-elevation patients showed that the proportions
of patients starting medication in-hospital were: 73.2% for
aspirin, 51.2% for ACE-inhibitors, 64.5% for beta-blockers,
and 65.6% for statins. The remaining patients to whom
these medications were administered in-hospital had started
taking them at least 1 month prior to hospital admission.
Comparison between the two surveys in terms of time
delay showed a reduction in the median time from
symptom onset to arrival at the emergency department,
from 210 min (105–625) in ACS-I to 170 min (90–420) in
ACS-II. This reduction was a result of decreases in both
time from symptom onset to ﬁrst call for help, from a
median 120 min (50–450) in ACS-I to 105 min (40–306) in
ACS-II, as well as time from ﬁrst call for help to emergency
room arrival, from a median 50 min (26–91) in ACS-I to
42 min (15–80) in ACS-II. A reduction in the length of stay
in the reporting department was also observed, with a
median stay of 8 days in EHS–ACS-I to 7 days in EHS–ACS-II.
In the 34 centres, a reduction was also noted, from 8 to 6
days.
Among patients with ST-elevation, 63.9% received primary
reperfusion treatment (51.8% of reperfused patients were
treated with PPCI, 7% with facilitated PCI, and 41.2% with
ﬁbrinolytic therapy, with or without rescue interventions).
The proportion of ST-elevation patients treated with
primary reperfusion therapy was directly related to
the time from symptom onset to emergency room arrival.
The rate of primary reperfusion was 74.4% among patients
with ST-elevation reaching the hospital within 6 h from
symptom onset (n ¼ 2116) and decreased to 54.8% and
25.2% for those reaching the hospital within 6–12 h
(n ¼ 301) and 12–24 h (n ¼ 338), respectively. A total of
1084 patients presenting with ST-elevation ACS did not
receive primary reperfusion therapy. The major reasons
were late arrival (30.1%), uncertain diagnosis (11.2%),
early resolution of ST-elevation (11.6%), and contraindica-
tions (6.5%). Additional reasons given by the treating
Table 1 Baseline, demographic, and clinical characteristics of ACS-I and ACS-II patients on the basis of the initial
electrocardiographic pattern
ST-elevation No ST-elevation
ACS-I (n ¼ 4431) ACS-II (n ¼ 3004) ACS-I (n ¼ 5367) ACS-II (n ¼ 3063)
Age (years) 63.4+ 13.0 62.5+ 13.1 65.8+ 12.0 66.1+ 12.1
Male gender (%) 71.6 74.1 64.4 67.0
BMI (mean) 27.0+ 4.1 27.0+ 4.3 27.4+ 4.4 27.4+ 4.8
Prior MI (%) 22.3 15.7 35.6 29.3
Prior PCI/CABG (%) 9.5 8.9 22.2 21.5
Diabetes mellitus (%) 21.1 21.4 23.5 26.7
Current smoker 42.8 45.6 27.0 28.0
Past smokers 20.3 22.6 26.8 29.8
Hypertension (%) 51.6 50.0 63.5 64.6
Hyperlipidaemia (%) 46.8 43.2 54.6 51.9
Family history of CAD (%) 27.4 29.8 29.3 32.6
Prior stroke/TIA (%) 5.9 5.2 8.1 7.3
Renal failure (%) 3.4 3.8 5.8 7.1
Heart rate (mean bpm) 79+ 20 78+ 19 79+ 19 79+ 20
Killip Class II, III, IV (%) 22.7 20.4 16.1 19.7
Continuous variables are presented as mean+ SD. BMI, body mass index; CAD, coronary artery disease; TIA, transient ischaemic
attack.
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physician included advanced age, premature death, patient
refusal, and lack of catheterization laboratory facilities.
In ACS-II, the most common complications during hospita-
lization were heart failure (12.4%), re-ischaemia/
re-infarction (8.0%), and paroxysmal or persistent atrial
ﬁbrillation (AF) (3.3%).
As expected, the majority of patients with ST-elevation
had a ﬁnal diagnosis of Q-wave MI (64%), whereas patients
admitted without ST-elevation were more likely to be diag-
nosed with UA (43%) or non-Q wave MI (38%). In the entire
cohort, 34.5% had a ﬁnal diagnosis of Q-wave MI, 28.2%
with non-Q wave MI, 9.0% with undetermined type of MI,
and 24.5% had UA. In 3.8% of the patients, the ﬁnal ACS diag-
nosis was not speciﬁed.
Post-discharge events occurring during the 30-day
follow-up period were available for 5213 hospital survivors
(85%), of whom 15.9% were re-hospitalized during the ﬁrst
month following admission to hospital. The majority of
re-hospitalizations of patients with ST or no ST-elevation
were cardiac related and were due to the need for coronary
angiography (4.4% and 4.8%), PCI (2.9% and 2.7%), coronary
artery bypass surgery (CABG) (1.5% and 2.0%), or other
cardiac surgery (0.3% and 0.2%). Among patients whose
initial ECG pattern was undetermined, the majority of
re-hospitalizations were due to other cardiac-related
reasons (10.8%). Non-cardiac-related reasons were the
cause of re-hospitalization in 2.3% of the patients.
Comparison of patients with ST-elevation
In both surveys, the baseline characteristics of the
ST-elevation patients were relatively similar (Table 1). A
better adherence to the use of recommended medications
was observed in the latter survey (Table 3, Figure 1).
A higher use of primary reperfusion therapy was observed
in ACS-II (63.9%) compared with ACS-I (55.8%), with a shift
from ﬁbrinolytic therapy to PPCI in ACS-II (Figure 3). Time
from symptom onset to hospital arrival and time from hospi-
tal arrival to reperfusion were both shorter in the second
survey, with a larger difference observed in time to PPCI
in comparison with time to ﬁbrinolytic therapy (Table 4).
Similar improved patterns were observed for the 34
centres and, in addition, the time from emergency room
arrival to ﬁbrinolytic therapy decreased from a median of
50 min to 30 min in the 34 centres. In the ACS-II survey, a
greater proportion of patients underwent coronary
Table 2 The in-hospital use of invasive and non-invasive diagnostic and therapeutic techniques
ST-elevation No ST-elevation
ACS-I (n ¼ 4431)
(%)
ACS-II (n ¼ 3004)
(%)
ACS-I (n ¼ 5367)
(%)
ACS-II (n ¼ 3063)
(%)
Total angiography 56.3 70.2 52.0 62.9
Total PCI 40.4 57.8 25.4 37.1
Total stent 31.0 52.4 18.1 33.8
CABG 3.4 2.9 5.4 7.4
Echocardiography 73.1 83.1 60.5 72.2
PA catheter 3.9 1.9 2.2 2.1
IABP 2.5 2.6 0.9 1.2
AICD 0.5 0.2 0.2 0.2
Holter 13.6 11.8 7.7 8.3
Permanent or temporary
pacemaker
2.8 3.1 1.8 1.5
Angiography, coronary angiography; PA, pulmonary artery; IABP, intra-aortic balloon pump; AICD, automatic internal cardiac
deﬁbrillator.
Table 3 In-hospital medical therapy
ST-elevation No ST-elevation
ACS-I (n ¼ 4431)
(%)
ACS-II (n ¼ 3004)
(%)
ACS-I (n ¼ 5367)
(%)
ACS-II (n ¼ 3063)
(%)
Aspirin 93.0 96.8 88.5 94.5
Warfarin 5.3 13.1 5.7 17.1
Heparin/LMWH 81.5 77.2 79.1 72.9
Ticlopidine/clopidogrel 36.1 69.8 27.6 67.4
GP IIb/IIIa inhibitor 19.6 30.7 10.0 20.8
ACE-inhibitors/angiotensin-II
receptor blocker
63.8 75.4 58.8 69.5
IV/oral b-adrenergic blocker 78.4 83.0 76.9 82.8
Statin 49.2 80.7 50.6 73.7
GP, platelet glycoprotein; ACE-I, angiotensin-converting enzyme-inhibitor; IV, intravenous.
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angiography, PCI, and stent implantation. In contrast, the
proportion of patients undergoing CABG surgery was lower
in ACS-II than ACS-I (Table 2). In the 34 centres, the use of
PPCI was even more pronounced (79%), and only 21% were
treated with ﬁbrinolytic therapy as compared with 43%
and 57%, respectively in ACS-I. In addition, the increased
use of coronary procedures, except CABG, was more pro-
nounced in the 34 centres between the two survey periods.
Comparison of patients with no ST-elevation
The baseline characteristics of the no ST-elevation patients
were quite similar in both the EHS–ACS-I and EHS–ACS-II
surveys (Table 1). Patients in ACS-II were more likely to be
treated with evidence-based medications (Table 3,
Figure 2). More coronary interventions during hospitali-
zation were performed in the second survey, with a higher
proportion of patients undergoing coronary angiography
and, among them, PCIs. Among the latter, stents were
placed in a greater proportion of patients in ACS-II than in
ACS-I. The frequency of CABG surgery was also higher in
this group of patients. Similar changes occurred in the 34
centres that participated in both surveys, but the increases
were more pronounced.
In-hospital and 30-day mortality
Crude mortality in-hospital and at 30 days was lower in
the total ACS-II cohort than the ACS-I cohort (Table 5).
The reduction in mortality from ACS-I to ACS-II was more
marked in the 34 centres, which participated in both
surveys (from 5.6 to 4.4% and 6.8 to 5.6% for in-hospital
and 30-day mortality, respectively). After adjustment in
multivariable analysis for the 34 centres, the odds ratio
(OR) for in-hospital mortality in ACS-II in comparison with
ACS-I was 0.58 (95% CI: 0.40–0.83), and for 30-day mortality,
0.66 (95% CI: 0.48–0.92).
Mortality rates in ACS-II differed according to the ECG
pattern on admission: the highest rates were noted for
patients presenting with undetermined ECG, who can be
characterized as a high-risk population with a greater preva-
lence of concomitant disease. The lowest rates were
observed for those without ST-elevation (Figure 4).
Mortality by ﬁnal diagnosis was higher for patients with
Q-wave MI, and highest among those with undetermined MI
(Figure 4). Among 246 patients in whom the ﬁnal diagnosis
was not speciﬁed (MI or UA), in-hospital and 30-day mor-
tality were 9.0 and 11.6%, respectively.
Discussion
The second Euro Heart Survey on ACS offers insight into con-
temporary diagnostic and therapeutic strategies applied for
Table 4 Timing of reperfusion in minutes (median, interquartile
range) and in-hospital coronary intervention among patients with
ST"—ACS-I vs. ACS-II
ACS-I
(N ¼ 4431)
ACS-II
(N ¼ 3004)
Symptom onset to ER 176 (90–465) 145 (80–330)
ER to primary reperfusion 59 (30–109) 53 (30–96)
ER to TLx (door to lysis) 40 (25–70) 37 (20–60)
ER to PPCI (door to balloon) 93 (60–170) 70 (40–125)
ER, emergency room; TLx, thrombolytic therapy.
Figure 3 Comparison of the use of primary reperfusion therapy in ACS-I and
ACS-II.
Figure 2 Comparison of treatment of no ST-elevation MI patients at dis-
charge in ACS-I and ACS-II in 34 centres that participated in both surveys.
Figure 1 Comparison of treatment of ST-elevation MI patients at discharge
in ACS-I and ACS-II in 34 centres that participated in both surveys.
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ACS patients. In addition, this survey sheds light on the
short- and intermediate-term prognosis of a wide spectrum
of ‘real world’ ACS patients. Moreover, this survey, per-
formed 4 years after the ﬁrst survey, enables the assessment
of temporal trends in the diagnosis, management, and out-
comes of ACS.
The comparison between the two surveys is encouraging
in several respects. Although the baseline characteristics
of the patients were similar during the two survey periods,
more extensive use of recommended medications was
noted for ACS patients with and without ST-elevation,
during hospitalization and at discharge, suggesting an
improvement in adherence to guidelines. Moreover, in the
latter survey, the use of coronary interventions such as cor-
onary angiography and PCI was also more frequent in both
patients with and without ST-elevation. However, additional
analysis is needed to determine whether a more aggressive
approach was administered to the patients who merit such
treatment: patients at intermediate-to-high risk. Although
the time from pain onset to reperfusion was shortened in
the second survey, there are still delays beyond the recom-
mended time for reperfusion therapy, and further research
is needed on how to improve public awareness of the
importance of early hospital arrival.
Among patients with ST-elevation, a slight increase in the
use of primary reperfusion was observed, accompanied by a
signiﬁcant shift from ﬁbrinolytic therapy to PPCI.
Nevertheless, a signiﬁcant proportion of ST-elevation
patients did not receive primary reperfusion treatment,
mainly because of late arrival, uncertain diagnosis upon
admission, and early ST-resolution, the latter of which is
viewed by some physicians as not requiring further reper-
fusion therapy. Of note, the rate of primary reperfusion
dropped from 74.4% among patients reaching the hospital
within 6 h from pain onset, to 25.2% among those reaching
the hospital 12–24 h from onset. A reduction in the time
from symptom onset to arrival at the emergency room was
also observed, suggesting that efforts to inform the public
of the need to respond immediately to symptoms of ACS
may be having an effect.
Moreover, in the 34 centres that participated in both
surveys, the increases in the use of evidence-based thera-
pies and interventions were accompanied by an even
greater reduction in mortality between ACS-I and ACS-II.
The relative risks of hospital and 30-day mortality were 42
and 34% lower in ACS-II in comparison with ACS-I, although
patient characteristics were similar. Therefore, the
improved outcome in the second survey may be partially
attributed to a signiﬁcant increase in guideline adherence
in these centres in ACS-II vs. ACS-I. Although the latter is
true as well for ST-elevation patients in the full ACS-II
cohort, the increase in the use of evidence-based therapies
and interventions among no ST-elevation patients seems to
have even preceded the publication of new guidelines.
As 92% of the ST-elevation patients in the ACS-II survey
were admitted to either coronary care units or cardiology
wards, it could be said that our data reﬂect the
state-of-the-art in cardiology departments. This may have
Table 5 Multivariable analysis of mortality: ACS-I vs. ACS-II
ACS-I
(N ¼ 10484)
ACS-II
(N ¼ 6385)
P-value
In-hospital mortality
n (%) 518 (4.9) 257 (4.0)
Unadjusted OR
(95% CI)
1.0 0.81 (0.69–0.94) 0.006
Adjusted OR (95% CI) 1.0 0.86 (0.73–1.01) 0.07
30-Day mortalitya
n (%) 600 (6.2) 310 (5.1)
Unadjusted OR
(95% CI)
1.0 0.81 (0.70–0.93) 0.004
Adjusted OR (95% CI) 1.0 0.85 (0.73–0.99) 0.04
aMissing: 7.6% in ACS-I and 4.4% in ACS-II.
Figure 4 In-hospital and 30-day mortality by initial ECG presentation and ﬁnal diagnosis (it should be noted that data on 30-day mortality were missing for
283 patients (4.4%).
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been a result of the type of hospitals willing to participate in
the survey on a voluntary basis.
A comparison of our current results for ST-elevation ACS
patients with those of the European subpopulation of the
GRACE (Global Registry Of Acute Coronary Events) registry
(n ¼ 2729),5 reveals similar rates of treatment with
aspirin, beta-adrenergic blockers, calcium-channel block-
ers, platelet glycoprotein IIb/IIIa inhibitors, and ACE-
inhibitors, whereas a greater proportion of patients in our
survey were treated with thienopyridines (69.8 vs. 48%)
and statins (80.7 vs. 58%). A comparison of medication at
discharge yielded similar results. With regard to reperfusion
therapy, the rate of use in the two surveys was similar (64
vs. 65% in EHS–ACS-II and GRACE, respectively), but PPCIs
were used more frequently in EHS–ACS-II. A comparison of
cardiac procedures shows that a greater proportion of
ST-elevation ACS patients underwent coronary angiography
in EHS–ACS-II in comparison with the GRACE patients
(70.2 vs. 53%). Comparison of in-hospital mortality showed
a lower death rate among EHS–ACS-II patients with
ST-elevation than among those in GRACE (5.3 vs. 7.8%).
Although these differences may primarily reﬂect differences
in enrolment criteria, they may also reﬂect a real improve-
ment in treatment with better prognosis.
Regarding non-ST-elevation ACS patients, the use of
evidence-based medications is similar to that reported by
the American CRUSADE national quality improvement
initiative,11 with the exception of glycoprotein IIb/IIIa
inhibitors, close to that observed in the lowest adherence
quartile in CRUSADE. Also, the proportion of patients dis-
charged with aspirin and beta-adrenergic blockers is closer
to the middle quartiles of CRUSADE hospitals. Thus, it
seems that the treatment strategies for no ST-elevation
ACS patients are similar on both sides of the Atlantic.
Limitations
Although 32 countries participated in EHS–ACS-II, the
number of centres that recruited patients in each country
were not representative of the countries’ populations. In
addition, as participation in the survey was voluntary, the
majority of the centres which participated could be charac-
terized as highly motivated, afﬁliated to academic insti-
tutions, likely to have catheterization laboratory facilities,
and to hospitalize ACS patients in either coronary care
units or cardiology departments, willing to expose their
practice to criticism, and more likely to adhere to guide-
lines. Therefore, we are unable to extrapolate our ﬁndings
to centres that did not participate in the survey. This limit-
ation is particularly relevant to the setting in which the
patients were treated in ACS-II, as the greater proportion
hospitalized in coronary care units may include slightly
different populations and treatment practices in comparison
with alternative settings. In addition, the survey did not
address the role of quality improvement interventions
used in the participating centres. Therefore, we were
unable to assess the extent to which the observed changes
in adherence could be attributed to local efforts towards
quality improvement. Furthermore, the inclusion of con-
secutive ACS patients could not be monitored, as on-site
auditing was not required by the survey protocol. Finally,
the comparison between the ﬁrst and second survey is
limited by the fact that not all the centres that participated
in the ﬁrst survey participated in the latter survey, and
additional centres were included in the second survey.
However, comparison of the 34 centres that participated
in both surveys yielded results that were comparable to
the full populations of the two surveys.
Conclusions
Data from the second Euro Heart Survey on ACS suggest an
increase in the level of adherence to guidelines for treat-
ment of ACS. The comparison of the 34 centres that partici-
pated in both surveys suggests that the early mortality
reduction observed in ACS-II was associated with improve-
ment in management and treatment, achieved from 2000
to 2004. It is reassuring to note that in most cases of patients
who did not receive evidence-based therapies, this was due
to contraindications or lack of indication for treatment
according to the current guidelines. This ﬁnding reinforces
the idea that guidelines should be tailored individually to
patients’ risk proﬁles. It is recommended that surveys be
performed periodically to continuously monitor the
implementation of emerging new guidelines among ACS
patients, and by doing so, improve quality of care and out-
comes over time. Attention to quality improvement inter-
ventions in future surveys would also be of great beneﬁt in
understanding the mechanisms contributing to changes in
guideline adherence.
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Appendix
Organization of the survey
Acute Coronary Syndrome Expert Committee: Alex Battler,
Shlomo Behar (Chairman), David Hasdai, Israel; Nicolas Danchin,
France; Anselm Gitt, Germany; Hector Bueno, Jaume Marrugat,
Spain; Frans Van de Werf, Belgium; Lars Wallentin, Sweden;
Yonathan Hasin, Israel and Gerasimos Filippatos, Greece (represen-
tatives of the ESC Working Group 27 Acute Cardiac Care).
Euro Heart Survey Board Committee: Anselm Gitt (Chairman),
Germany; Maarten Simoons (Past-Chairman), The Netherlands;
David Wood (Past-Chairman), UK; Angeles Alonso, Spain; Alex
Battler, Israel; Shlomo Behar, Israel; Eric Boersma, The
Netherlands; Harry Crijns, The Netherlands; Kim Fox, UK; Michel
Komajda, France; Malika Manini, France; Keith McGregor, France;
Barbara Mulder, The Netherlands; Sylvia Priori, Italy; Lars Ryde´n,
Sweden; Luigi Tavazzi, Italy; Alec Vahanian, France; Panos Vardas,
Greece; William Wijns, Belgium; Uwe Zeymer, Germany.
Euro Heart Survey Team (European Heart House—FRANCE):
Vale´rie Laforest, Data Monitor; Charles Taylor, Database
Administrator; Claire Bramley, Data Monitor; Malika Manini,
Operations Manager.
Principal Investigator Centre (Tel Hashomer, Israel): Shlomo Behar
(Survey Chairman), Lori Mandelzweig (Research Coordinator),
Valentina Boyko (Statistician).
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National Coordinators: Austria, Kurt Huber; Belgium, Guy De
Backer; Bulgaria, Vera Sirakova; Czech Republic, Roman Cerbak;
Denmark, Per Thayssen; Finland, Seppo Lehto; France, Jean-
Jacques Blanc, Franc¸ois Delahaye; Georgia, Bondo Kobulia;
Germany, Uwe Zeymer; Greece, Dennis Cokkinos; Hungary, Kristof
Karlocai; Ireland, Ian Graham, Emer Shelley; Israel, Shlomo Behar;
Italy, Aldo Maggioni; Lithuania, Virginija Grabauskiene;
Netherlands, Jaap Deckers; Norway, Inger Asmussen; Poland,
Janina Stepinska; Portugal, Lino Gonc¸alves; Russia, Vyacheslav
Mareev; Serbia & Montenegro, Zorana Vasiljevic; Slovakia, Igor
Riecansky; Slovenia, Miran F. Kenda; Spain, Angeles Alonso, Jose´
Luis Lopez-Sendon; Sweden, Annika Rosengren; Switzerland, Peter
Buser; Turkey, Tugrul Okay; Ukraine, Oleg Sychov; UK, Peter
Schoﬁeld.
There was no national coordinator in the participating countries
which are not mentioned in the above list.
Participating Countries (number of patients included),
Investigators, and Data Collection Ofﬁcers:
Austria (116): Gunther Christ, Kurt Huber, Peter Dolliner, Kadriye
Aydinkoc, Karim Kalla Vienna.
Belgium (80): Christiaan Vrints, Els Van Hertbruggen Edegem;
V. Legrand, Joseph Dib Liege; E. Schroeder, Juliette Domange Yvoir.
Bulgaria (207): Assen Rachev Goudev, Desislava Bojidarova
Bojadgieva Pleven; Mladen Grigorov, Georgi Todorov. Georgi
Grigorov, Nina Gocheva, Elina Trendaﬁlova, Temenuga Donova,
Vera Bogdanova, Soﬁa; Borislav Boyanov Borisov, Stara Zagora;
Vera Sirakova, Jordan Krasnaliev, Varna.
Croatia (160): Ante Samodol, Sibenik; Vjekoslava Raos, Zrinka
Trstenjak, Vjeran Nikolic Heitzler, Zdravko Babic, Nikola Bulj,
Zagreb.
Cyprus (29): Marios Ioannides, Larnaca; Joseph A. Moutiris,
Paphos.
Czech Republic (163): J. Spinar, Jiri Spac, Ota Hlinomaz, Petr
Bouchal Brno; Jindrich Florian, Sirous Yaghmaee Cesky Krumlov;
Alena Krizova, Pardubice; J. Bruthans, Andrej Bajo, Roudnice nad
Labem.
Denmark (30): P. Thayssen, Helle Cappelen Odense.
Egypt (25): Hossam Kandil, Khalid Tammam Cairo.
Estonia (37): Toomas Marandi Tallin.
Finland (115): Kari Virtanen, Mervi Pietila, Helsinki; Juha
Mustonen, Irmeli Juntunen Joensuu; Seppo Lehto, Kirsti
Savolainen Kuopio.
France (387): J.P. Bassand, Jerome Varini, Besancon; Yves Cottin,
Dijon; Nicolas Danchin, Sylvie Marinier Paris; Herve´ Le Breton,
Corinne Heautot, Christine Poulain, Rennes; Jean Marco, Frederic
Petit, Toulouse; Michael Angioi, Tatiana Dabrowski, Vandoeuvre les
Nancy; Jean Louis Georges, G. Gibault-Genty, J. Schwob, Fadela
Pousset, Versailles.
Georgia (63): David Maisuradze, Irma Aladashvili Rustavi; Bondo
Kobulia, Irina Iashi, Tbilisi.
Germany (55): Ulrich Tebbe, Detmold; J. Niebauer, K. Drechsler,
Leipzig; A. Gitt, Harm Wienbergen, Ludwigshafen am Rhein.
Greece (375): Gerasimos Filippatos, Virginia Markou, Ioannis
Fotiadis, Dimitrios A. Korres, Athanasios Manginas, D. Cokkinos,
Anastasia Tsiavou, Ilias K. Karabinos, Athens; Nikos Kafkas, Khﬁsia;
Alexandros Gotsis, Komotini; Ioannis Skoularigis, Larisa; Foussa
Stefanos, Nikolaos Patsourakos, Apostolou Thomas, Eftihia
Hamodraka Pireus; Antonios Kassimatis, Kostas S. Liveris, Petros
Stravopodis, Zakynhtos.
Hungary (70): Istvan Preda, Eva Csoti Budapest; Janos Takacs,
Mosonmagyarovar; Aranka Kovacs, Istvan Bodonovits, Ferenc
Kovacs Szentes.
Israel (592): Leonardo Reisin, Yosi Blayer Ashkelon; Doron Zahger,
Irit Rabinowitz, Beer Sheva; Edo Kaluski, Jana Babkin, Beer Yakov;
Avraham Shotan, Mark Kazatsker, Hadera; Haim Hammerman,
Robert Dragu, Uri Rosenschein, Shmuel Rosenschein, Haifa;
Jonathan Balkin, Shiri, Jerusalem; Nathan Roguin, N. Clauzner,
Nahariya; Mohammed Omary, Nazareth; A. Battler, Boris Napach,
Zaza Shvili, Petach Tikva; Hanoch Hod, Shlomo Matetzky, Tel
Hashomer; Arie Roth, Yehuda Levi, Tel-Aviv; Y. Hasin, Anna
Bogochinsky, Hanody Saadi, Tiberias; Alon Marmour, Olga Truchin,
Tsfat.
Italy (674): Giancarlo Scognamiglio, Acerra; Giuseppe
Scaramuzzino, Bologna; Luigi Meloni, Enrico Onnis, Cagliari;
Gaspare Ferrantelli, Castelvetrano; Francesco Gentile, Elena
Mangiarotti Cinisello Balsamo; Annamaria Nicoletti, Vena Silvio,
Cosenza; Grigolato Michele, Desenzano Del Garda; Silva Severi,
Marco Breschi, Grosseto; Massimo Conti, Guastalla; Luigi Leonzio,
Valerio Alfonso, Lanciano; Antonio Pesola, Lorenza Robiglio, Lido
Di Camaiore; Felice Achilli, Andrea Farina Merate; Antonio Mafrici,
Chiara De Benedetta, Bruno Brusoni, Marco Negrini, Milan;
Gianluigi Olivato, Monfalcone; Antonino Rotolo, Palermo; Federico
Ferraris, Pietra Ligure; Anna Toso, Prato; Albarosa Ruggeri, Reggio
Calabria; Sergio Bongioanni, Ernesto Iazzolino, Piras Rivoli;
Alessandro Boccanelli, Cesare Greco, Maria Luisa Finocchiaro,
Roberto Luongo Roma; Emanuele Carbonieri, San Bonifacio;
Eugenio Vinci, Siracusa.
Lithuania (87): D. Vasiliauskas, Ruta Barbaskiene, Kaunas; Vitas
Vysniauskas, Daiva Petraskiene, Marijampole; Birute Petrauskiene,
Eduardas Subkovas, Rasa Palsauskaite, Taida Ivanauskiene, Sigita
Glaveckaite, Egle Sadauskiene Vilnius.
The Netherlands (580): C. Werter, Adrie Van Den Dool Roermond;
M. Bijl, Saskia Versluis, Dordrecht; R. Haan, Christel Ephraim,
Harderwijk; Leo Baur, Heerlen; R. Brons, Meppel; Harry Crijns,
R. Nieuwlaat, Heidi Frensen, Maastricht; D.C.A. van Hoogenhuyze,
J. Deckers, Chris Jansen, M.J. Veerhoek, Maria Kamps, C.M.
Leenders, Rotterdam; J.B. Winter, Herman Broers, Tilburg;
J. Meeder, C. Firanescu, Venlo; R. Brons, K. Nijenbrinks,
K. Thomas, Ingrid Middelveld, Zwolle.
Poland (417): Wodzimierz J. Musia, Agnieszka Kuklinska,
Bialystok; Grzegorz Pulkowski, Marcin Majer, Bydgoszcz; Bogdan
Zbyszynski, Ciechanow; A. Rynkiewicz, Jerzy Bellwon, Tuchacz,
Gdansk; Michal Tendera, Rafal Wyderka, Katowice; Elzbieta Zinka,
Wojciech Jablonski, Koszalin; A. Cieslinski, Przemyslaw Mitkowski,
Poznan; Janusz Kostrzewa, Roman Bytner, Rypin; Janina Stepinska,
Marek Batogowski, Warsaw; Andrzej Budaj, Piotr Kokowicz, Pawel
Lewandowski, Marek Roik, Grzegorz Opolski, Jerzy Rekosz,
Warszawa.
Portugal (334): Maria Jose Loureiro, Almada; Rafael Ferreira,
Joao Ribeiro Amadora; Pedro Monteiro, Coimbra; Jorge Mimoso,
Rui Alexandre C Candeias, Faro; Decio Pereira, Funchal; Joao
Carlos Araujo Morais, Leira; J. A. Correia da Cunha, Maria Jose
Correia, Rui Ferreira, Antonio Fiarresga Lisbon; Cristina Gavina,
teresa Pinho, Porto.
Romania (76): Maria Dorobantu, Rodica Niculescu, Bucharest;
Cristian Statescu, G. Georgescu, Radu A. Sascau Lasi.
Russian Federation (90): Nikolai. A. Gratsiansky, A.D. Erlikh,
Simon Matskeplishvili, Yuri Buziashvili Moscow; Dmitry Duplyakov,
Togliatti.
Serbia and Montenegro (177): Mirko Colic, Milosav Tomovic,
Zorana Vasiljevic, Gordana Krljanac, Milutin Miric, Natasa
Markovic, Belgrad; N. Radovanovic, Tijana Momcilov Popin,
Sremska Kamenica.
Slovenia (48): Miran Sebestjen, Andrej Pernat, I. Kranjec,
Ljubljana.
Spain (1030): Antonio Radova´n, Girona; Gurruchaga, Guipu´zcoa;
Dra. Martı´n, Zamora; Laperal/Casado, Zaragoza; Dra Bisbe y
Loubad, Girona; Vicente Bartomeu y Dra. Carrillo; Eduardo
Benı´tez Cano, Plasencia; Miguel De Miguel; Francico Penas,
Pontevedra; Casares; Juan Ortega Bernal, Cartagena; Francisco
Calvo Iglesias, Vigo; Joaquı´n Barba/Jesu´s Herreros; Agustı´n
Ardiaca, Lleida; Salvador/Pablo Aguar, Valencia; Munilla, Logron˜o;
Fernando Aro´s/Emilio Sanz, Vitoria; Fe´lix Noriega, Povisa; Velasco
y Joaquina Belchi, Valencia; Valdepen˜as; Pastor Torres y Dra.
Melguizo, Sevilla; Jesu´s Aguirre, Bilbao; A´ngel Llamas, Donostia;
Martos, Almerı´a; Eduardo De Teresa, Ma´laga; Carlos Pagola,
Jae´n; Luis Rodrı´guez Padial, Toledo; Sogorb Garri/Dra. Oliver,
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Alicante; Magda. Heras/Amadeo Betrı´u, Barcelona; Antonio
Mercha´n, Badajoz; Enric Esplugas/M. Ribas, Barcelona; Martin
Luengo/Pedro Pabo´n; Barrenechea Benguria, Baracaldo; Placer/J.
Sa´nchez, Zaragoza; Jose´ M. Cruz Ferna´ndez, Sevilla; Atilano
Sa´nchez/Poveda, Santander; Federico Valle´s, Co´rdoba; Carlos
Macaya/J. Ferrero, Madrid; Cayetano Permanyer, Barcelona;
Burgos Cornejo, Sevilla; He´ctor Bueno, Madrid; Jose Luı´s Martı´,
Granada; Francisco Ferna´ndez Avile´s/Pedro Luis Sa´nchez; Jordi
Bruguera/L. Recasens, Barcelona; Abizanda; In˜aki Lecuona;
Lorenzo Lopez Bescos/Ana Huelmos; J. Farre´/Romero, Madrid;
Luis Alonso Pulpo´n Javier Ortigosa, Madrid; Alfredo Bardajı´,
Tarragona; Antonio Monto´n, Burgos; Joan Sala, Girona; Carmen
Corona/Dra. Adamuz, U´beda.
Sweden (157): Annika Rosengren, Gorel Hultsberg-Olsson, Lena
Bjorck, Go¨teborg; Juhlin Tord, Birgitta Ohlsson, Malmo.
Switzerland (48): Dominique Evequoz, Ian Charvat, Brig.
Tunisia (28): Habib Gamra, Khaldoun Ben Hamda, Faten Triki,
Zohra Dridi, Faouzi Addad, Fethi Betbout, Monastir.
Turkey (30): Zeki Ongen, Hakan Erkan, Istanbul.
Ukraine (63): Olena Koval, Andrey P. Ivanov, Pavel A. Kaplan,
Dnipropetrovsk; Vasyl Netiazhenko, Lykov Oleg, Kiev.
UK (42): P.M. Schoﬁeld, G. Charman, Cambridge; K. Fox, D. Peter,
I. Hassan.
Industry Sponsor: Eli Lilly.
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